Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Reece

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Blood|April 1, 1991
High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adultsG L Phillips, D E Reece, J D Shepherd, et al.
Leukemia & Lymphoma|July 1, 1997
Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blastsB I Dalal, V Wu, M J Barnett, et al.
Bone Marrow Transplantation|May 13, 1998
Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factorsS R Jackson, M G Tweeddale, M J Barnett, et al.
Bone Marrow Transplantation|November 26, 2013
Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantationC O Freytes, D H Vesole, J LeRademacher, et al.
Bone Marrow Transplantation|March 29, 2000
Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemiaC L Toze, J D Shepherd, J M Connors, et al.
Clinical Breast Cancer|March 20, 2002
Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancerD E Reece, K A Foon, M Battacharya-Chatterjee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Allografting for indolent lymphoid neoplasmsC L Toze, J D Shepherd, J M Connors, et al.
Leukemia|February 20, 2009
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialC B Reeder, D E Reece, V Kukreti, et al.
Bone Marrow Transplantation|June 26, 1999
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's diseaseD E Reece, T J Nevill, A Sayegh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant RegistryH M Lazarus, P A Rowlings, M J Zhang, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Blood|April 1, 1991
High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adultsG L Phillips, D E Reece, J D Shepherd, et al.
Leukemia & Lymphoma|July 1, 1997
Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blastsB I Dalal, V Wu, M J Barnett, et al.
Bone Marrow Transplantation|May 13, 1998
Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factorsS R Jackson, M G Tweeddale, M J Barnett, et al.
Bone Marrow Transplantation|November 26, 2013
Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantationC O Freytes, D H Vesole, J LeRademacher, et al.
Bone Marrow Transplantation|March 29, 2000
Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemiaC L Toze, J D Shepherd, J M Connors, et al.
Clinical Breast Cancer|March 20, 2002
Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancerD E Reece, K A Foon, M Battacharya-Chatterjee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Allografting for indolent lymphoid neoplasmsC L Toze, J D Shepherd, J M Connors, et al.
Leukemia|February 20, 2009
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trialC B Reeder, D E Reece, V Kukreti, et al.
Bone Marrow Transplantation|June 26, 1999
Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's diseaseD E Reece, T J Nevill, A Sayegh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant RegistryH M Lazarus, P A Rowlings, M J Zhang, et al.
Pageof 8